|Example 1. Frequentist AD|
Authors are referred to the CONSORT 2010 statement [3, 4] for examples.
Example 2. 2-stage Bayesian biomarker-based AD with RAR
In a methods paper, Gu et al.  detail Bayesian logistic regression models for evaluating treatment and marker effects at the end of stage 1 and 2 using non-informative normal priors during RAR and futility early stopping decisions. Strategies for variable selection and model building at the end of stage 1 to identify further important biomarkers for use in RAR of stage 2 patients are described (part of item 3b), including a shrinkage prior used for biomarker selection with rationale.